Solid tumours trang 1 tải miễn phí từ TAILIEUCHUNG

"Solid tumours" trang 1 - tải miễn phí từ Tailieuchung

High Oct4 expression: Implications in the pathogenesis of neuroblastic tumours

High Oct4 expression: Implications in the pathogenesis of neuroblastic tumours

8 55 1

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: A prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: A prospective multicentre study in France in patients with solid tumours (the ZOHé study)

13 38 1

Prognostic significance of KLF4 in solid tumours: An updated meta-analysis

Prognostic significance of KLF4 in solid tumours: An updated meta-analysis

11 8 1

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours

10 43 1

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours

9 21 1

Báo cáo sinh học:

Báo cáo sinh học: " AAV2-mediated in vivo immune gene therapy of solid tumours"

1 20 0

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

20 53 0

Ebook Paediatrics and child health: Part 2

Ebook Paediatrics and child health: Part 2

292 67 0

Screening and surveillance of multiple solid tumours using plasma placental-like chondroitin sulfate A (pl-CSA)

Screening and surveillance of multiple solid tumours using plasma placental-like chondroitin sulfate A (pl-CSA)

9 83 0

Radiosensitization of clioquinol and zinc in human cancer cell lines

Radiosensitization of clioquinol and zinc in human cancer cell lines

9 20 1

Validation of a frailty index in older cancer patients with solid tumours

Validation of a frailty index in older cancer patients with solid tumours

8 27 1

Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells

Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells

10 45 1

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

12 23 1

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

13 45 3

Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: Experience of the Polish Paediatric Solid Tumours Study Group

Isolated central nervous system relapses in patients with high-risk neuroblastoma -clinical presentation and prognosis: Experience of the Polish Paediatric Solid Tumours Study Group

9 22 1

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer

9 72 1

Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer

Metformin and longevity (METAL): A window of opportunity study investigating the biological effects of metformin in localised prostate cancer

12 41 1

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma - differences in histological subtypes

The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma - differences in histological subtypes

12 33 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.